Vertex Diversifies on CF Cash While CASGEVY Durability and Renal Bet Face Proof

Vertex Reports Strong Q3 2026 Results, Raises Full-Year Guidance

Vertex Pharmaceuticals Incorporated reported strong consolidated financial results for the third quarter ended September 30, 2026, with total revenue increasing 12% to $3.44 billion compared to the third quarter of 2025. The company also raised its full-year 2026 revenue guidance to $13.15 billion to $13.25 billion. This growth was primarily driven by continued performance of cystic fibrosis therapies and contributions from CASGEVY, JOURNAVX, and PALSONIFY. Vertex further solidified its portfolio by closing the Crinetics Pharmaceuticals acquisition, establishing a fourth commercial pillar in rare endocrine diseases, and is preparing for a fifth in renal medicine with the upcoming povetacicept PDUFA date on November 30, 2026.

• Strong Financial Performance and Raised Guidance: Vertex achieved $3.44 billion in total revenue for Q3 2026, a 12% increase year-over-year, driven by cystic fibrosis therapies and new product contributions. Consequently, the company raised its full-year 2026 revenue guidance to $13.15 billion to $13.25 billion, reflecting continued growth and contributions from recent launches and acquisitions.
• Strategic Expansion into New Therapeutic Areas: Vertex established a fourth commercial pillar in rare endocrine diseases through the acquisition of Crinetics Pharmaceuticals, adding PALSONIFY to its portfolio. Furthermore, the company is preparing to launch its fifth commercial franchise in renal medicine with povetacicept, which has a PDUFA date of November 30, 2026, for IgA Nephropathy.
• Significant Growth and Regulatory Milestones for Marketed Products: CASGEVY revenue surged 30% quarter-over-quarter to $99 million, and JOURNAVX prescriptions increased over 40% quarter-over-quarter, generating $58 million in revenue. Additionally, CASGEVY received FDA approval for children aged 2 and older with severe sickle cell disease and transfusion-dependent beta thalassemia, significantly expanding its eligible patient population.

Addressing Unmet Needs in IgA Nephropathy: A New Commercial Pillar

Recent literature underscores persistent progression to kidney failure despite optimized supportive care, with about 30-50% of the patients with IgAN developing end-stage kidney disease. Focus has shifted toward high-risk progressors, post-transplant recurrence, refractory disease, and late-diagnosed or elderly populations requiring precision targeted therapies.

• Pediatric and young adult transplant recipients at risk of graft loss from recurrence: In 1915 patients with IgAN aged 0 to 25 years, IgAN was associated with higher risk of graft loss (adjusted hazard ratio [aHR], 1.35; 95% CI, 1.21-1.50; P < .001) compared with dysplasia. Graft loss was attributed to recurrent disease in 5.4% of patients with IgAN. Patients receiving a parental living-donor kidney were more likely to report graft loss from recurrent disease compared with patients with a nonparental living donor (aHR, 0.52; 95% CI, 0.31-0.91; P = .02). Posttransplant prednisone use was not associated with improved graft survival (P = .2).

• Post-transplant IgA deposits with active pathology and graft dysfunction: Out of 1036 kidney transplants, 760 graft biopsies were performed. Sixty-four cases had post-transplant deposition of IgA (8%). Group A (pathogenic IgAD) had 46 cases (71.9%), out of which 8 had active IgA nephropathy (endocapillary proliferation, crescents, and IgA vasculitis), and 38 had inactive IgAD. In group A, 22 (47.8%) presented with graft dysfunction, 8 (17.3%) with isolated proteinuria, and 14 (30.4%) patients presented with a combination. Active IgA pathologies may occur early in the post-transplant course, may have significant graft dysfunction, and need proactive management. Long-term follow-up is essential.

• Rapid progressors and high proteinuria populations: A total of 76 patients (76 of 193, 39.4%) had rapid progression in 3 years (≥5 ml/min per 1.73 m decline in estimated glomerular filtration rate [eGFR] per year). A total of 72 patients (72 of 195, 36.9%) experienced the composite outcome (CO), defined as ≥50% fall in eGFR, eGFR < 15 ml/min per 1.73 m, commenced kidney replacement therapy or death, in 3 years. At each scheduled follow-up, achievement of proteinuria level < 1 g/d significantly delayed the time to the CO. In the German Chronic Kidney Disease cohort, 28% of the patients experienced the CKE within 6.5 years, supporting albuminuria as a surrogate to assess risk of poor kidney outcomes.

• Elderly and late-diagnosed patients with severe phenotype: Among 127 patients aged ≥ 60 years at diagnosis, median estimated glomerular filtration rate (eGFR) was 25 ml/min per 1.73 m, 81% had proteinuria ≥ 1000 mg/g creatinine, 35% and 17% had CKD stages 4 and 5, respectively. Forty-five patients progressed to kidney failure and 86 died. In a US cohort of 4375 patients (mean age 47.7 years, 62.7% male), 74.6% of patients were at CKD stage ≥3, with mild to moderate mesangial hypercellularity (47.3%), segmental sclerosis (65.0%), tubular atrophy ≥25% (57.4%), and crescents (18.5%).

• Refractory disease and molecularly targeted populations: Refractory disease is defined as individuals that present a 24 h urinary protein persistently >1 g after at least two rounds of regular steroids (methylprednisolone or prednisone) and/or immunosuppressant therapy (e.g., mycophenolate mofetil), or who do not tolerate regular steroids and/or immunosuppressant therapy. Core research themes clustered into three domains: complement inhibition (e.g., C5 blockade), B-cell-directed therapy (including BAFF/APRIL modulation), and mucosal immune regulation. Elevated serum levels of both BAFF and APRIL are observed in patients with IgAN and correlate with disease severity.

Unpacking Povetacicept's Pivotal RAINIER Trial Design in IgAN

Recent IgA nephropathy trials evaluate targeted systemic, hemodynamic, and immunologic strategies in high-risk proteinuric populations on optimized supportive care. Designs range from short proteinuria-based interim analyses to 2-year kidney function assessments with extended follow-up. Endpoints consistently center on proteinuria reduction and eGFR preservation with safety evaluation.

Evolving IgA Nephropathy Treatment Landscape and Povetacicept's Entry

Management of IgA nephropathy (IgAN) historically relied on supportive care with renin-angiotensin system inhibition, with a suggested 6 months of immunosuppressive therapy considered for patients at high risk of progressive kidney function decline despite ≥90 days of optimized supportive care. Systemic corticosteroids remained controversial due to suboptimal study designs, inadequate implementation of standard of care and inconsistent adverse events data collection. Two well designed, adequately powered, multi-centre randomized controlled trials, the STOP-IgAN and TESTING studies, reported contrasting kidney outcomes and both independently reported greater adverse events with corticosteroids. The TESTING study showed that a 6- to 9-month course of oral methylprednisolone is an effective regimen to protect kidney function in high-risk patients with IgAN, but also demonstrated safety concerns, with the reduced-dose regimen reported to be beneficial, with successfully increased safety. A novel targeted release formulation of budesonide, Nefecon, designed to inhibit galactose-deficient IgA1 formation underlying IgAN pathophysiology, showed promising results in the Phase 3 NefIgArd trial (NCT03643965), which demonstrated a meaningful reduction in proteinuria and eGFR decline versus placebo with an acceptable safety profile. In patients from mainland China, the primary efficacy end point was 9.6 ml/min per 1.73 m2 (95% confidence interval, 2.0 to 19.8) in favor of nefecon versus placebo, and time to confirmed 30% eGFR reduction or kidney failure was substantially delayed (patients with an event: 9%) versus placebo (30%; hazard ratio, 0.21; 95% confidence interval, 0.04 to 0.73).

Non-immunosuppressive strategies targeting hemodynamic and fibrotic pathways have become integral to contemporary supportive care, particularly in patients with chronic kidney damage. In PROTECT, a double-blind, randomised, active-controlled, phase 3 study across 134 clinical practice sites in 18 countries, patients with biopsy-proven primary IgA nephropathy and proteinuria of at least 1·0 g per day despite maximised renin-angiotensin system inhibition were randomly assigned to sparsentan (target dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once daily). eGFR chronic 2-year slope (weeks 6-110) was -2·7 mL/min per 1·73 m per year versus -3·8 mL/min per 1·73 m per year (difference 1·1 mL/min per 1·73 m per year, 95% CI 0·1 to 2·1; p=0·037), and at 110 weeks proteinuria was 40% lower in the sparsentan group than in the irbesartan group (-42·8%, 95% CI -49·8 to -35·0, with sparsentan versus -4·4%, -15·8 to 8·7, with irbesartan; geometric least-squares mean ratio 0·60, 95% CI 0·50 to 0·72). In ALIGN, a randomised, double-blind, placebo-controlled, phase 3 trial (133 sites, 20 countries) in adults with biopsy-proven IgA nephropathy, eGFR of at least 30 mL/min per 1·73 m, and urinary protein excretion of at least 1·0 g/day while receiving renin-angiotensin system inhibition, change from baseline in eGFR at week 136 was -7·5 mL/min per 1·73 m (95% CI -9·2 to -5·8) with atrasentan 0·75 mg once daily and -9·9 mL/min per 1·73 m (-11·7 to -8·1) with placebo (between-group difference 2·4 mL/min per 1·73 m; 95% CI -0·1 to 4·8; p=0·057). In a pre-specified analysis of the DAPA-CKD trial, in 270 participants with IgA nephropathy followed for median 2.1 years, the primary composite endpoint of sustained decline in eGFR of 50% or more, end-stage kidney disease, or death from a kidney disease-related or cardiovascular cause occurred in six (4%) participants on dapagliflozin 10mg and 20 (15%) on placebo (hazard ratio, 0.29; 95% confidence interval, 0.12, 0.73), with mean rates of eGFR decline of -3.5 and -4.7 mL/min/1.73m/year, respectively.

Disease-specific immunologic approaches targeting B-cell dysregulation and complement activation have advanced rapidly, with recent approvals including Nefecon, sparsentan, iptacopan, atrasentan, and sibeprenlimab. A proliferation-inducing ligand (APRIL) mediates B-cell dysregulation and overproduction of pathogenic galactose-deficient IgA1 (Gd-IgA1), and several agents targeting APRIL, including atacicept, telitacicept, zigakibart and sibeprenlimab, are under investigation. In a systematic review with pairwise and network meta-analysis of seven trials (1,590 adults) evaluating telitacicept, atacicept, and sibeprenlimab, BAFF/APRIL-pathway inhibition reduced proteinuria versus placebo (SMCR -0.73, 95% CI -0.88 to -0.58, p < 0.001, I = 0%) and showed a small difference in eGFR favouring active treatment (+0.21, 95% CI 0.04 to 0.38, p = 0.016, I = 0%). In a phase 2, multicenter, double-blind, randomized, placebo-controlled trial, the geometric mean ratio reduction (±SE) from baseline in the 24-hour urinary protein-to-creatinine ratio at 12 months was 47.2±8.2%, 58.8±6.1%, 62.0±5.7%, and 20.0±12.6% in the sibeprenlimab 2-mg, 4-mg, and 8-mg groups and the placebo group, respectively, with least-squares mean (±SE) change in eGFR of -2.7±1.8, 0.2±1.7, -1.5±1.8, and -7.4±1.8 ml per minute per 1.73 m. Long-term open-label extension data with atacicept 150 mg through 96 weeks showed sustained reductions in Gd-IgA1 (−66%±2%), percentage of participants with hematuria (−75%; 95% confidence intervals, −87 to −59), and UPCR (−52%±5%), with mean annualized slope of eGFR of −0.6±0.5 ml/min per 1.73 m. Iptacopan inhibits complement factor B and has received accelerated US Food and Drug Administration approval, with interim phase 3 data showing significant proteinuria reduction versus placebo.